MedTrace Logo

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

NCT03453801 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-02-13

No results posted yet for this study

Summary

The purpose of this study is provide a better understanding of the adaptive immune response to the licensed influenza vaccines in children.

Conditions

Interventions

BIOLOGICAL

Fluzone®

Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine): The pediatric dose (6-35 months) will be supplied in a prefilled, single dose syringe, 0.25 mL (no preservative). Each 0.5 mL dose of Fluzone® Quadrivalent (36 months-adult) will be supplied in a prefilled, single dose syringe, 0.5 mL (no preservative). Both formulations given IM.

BIOLOGICAL

FluMist®

FluMist® Quadrivalent: live, attenuated influenza virus vaccine quadrivalent, given by intranasal spray

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia L Dekker, MD · Stanford University

  • Mark M Davis, PhD · Stanford University

  • Philip M Grant, MD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
10 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-01-14
Completion
2019-01-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03453801 on ClinicalTrials.gov